Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA)
吡咯替尼联合白蛋白紫杉醇作为 N0/N1mi、HER2 + 早期乳腺癌辅助治疗的 II 期试验的原理和设计 (PHAEDRA)
期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-022-09346-1
Wang, Changjun; Zhou, Yidong; Lin, Yan; Mao, Feng; Guan, Jinghong; Zhang, Xiaohui; Shen, Songjie; Wang, Xuejing; Zhang, Yanna; Pan, Bo; Zhong, Ying; Peng, Li; Cao, Xi; Yao, Ru; Zhou, Xingtong; Xu, Chi; Xu, Ying; Sun, Qiang